SYRS, US8719201096

Syros Pharmaceuticals approved a wind-down: what it means for Syros Pharmaceuticals stock

Published on 10/01/2026 at 15:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Syros approved a wind-down on February 28, 2025 after its Phase 3 failure. Syros Pharmaceuticals stock remains tied to one lead asset.

SYRS, US8719201096, Illustration mit AI erstellt.

Syros Pharmaceuticals (US8719201096) approved a wind-down on February 28, 2025 after its lead Phase 3 trial failed to meet its primary endpoint. The decision still defines the investment case around the company's remaining assets and its OTC-traded security.

Wind-down follows trial failure

According to Edgechat, the SELECT-MDS-1 study tested tamibarotene with azacitidine in patients with higher-risk myelodysplastic syndrome. The Phase 3 trial failed to meet its complete response endpoint, triggering an event of default under Syros' loan and security agreement with Oxford Finance.

The board's February 28, 2025 decision authorized voluntary delisting from Nasdaq and a creditor-approved wind-down. The company planned to file a Form 25 in March 2025, followed by a Form 15 tied to deregistration, according to Edgechat.

One lead asset remains

Syros' investor-relations page says the company is committed to developing treatments for frontline hematologic malignancies, including cancers of the blood and bone marrow. Its stated approach centers on therapies that regulate gene expression, while tamibarotene has been the central clinical program.

The historical pipeline also included SY-2101, an oral formulation of arsenic trioxide for acute promyelocytic leukemia, and SY-5609, a cyclin-dependent kinase 7 inhibitor for selected solid tumors. Those programs show why the wind-down matters: the failed Phase 3 program narrowed a business once built around several clinical candidates to a much smaller asset base.

OTC quote stays at microcap level

On September 11, 2026, SYRS was quoted at USD 0.0004 in OTC trading, with 62,234 shares changing hands. The same dated quote showed a prior close of USD 0.0004 and a 52-week range of USD 0.0000 to USD 0.0200.

For investors, the central issue is corporate status rather than a conventional earnings cycle. Syros Pharmaceuticals' Healthcare and Biotechnology classification remains visible in its company profile, but the February 2025 wind-down and the Phase 3 failure are the key facts shaping how the security is viewed.